Solara Active Pharma Sciences Ltd
NSE:SOLARA

Watchlist Manager
Solara Active Pharma Sciences Ltd Logo
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Watchlist
Price: 799.35 INR 4.98% Market Closed
Market Cap: 38.4B INR
Have any thoughts about
Solara Active Pharma Sciences Ltd?
Write Note

Solara Active Pharma Sciences Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Solara Active Pharma Sciences Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
Solara Active Pharma Sciences Ltd
NSE:SOLARA
Note Receivable
â‚ą39.4m
CAGR 3-Years
22%
CAGR 5-Years
5%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Note Receivable
â‚ą3.7B
CAGR 3-Years
9%
CAGR 5-Years
1%
CAGR 10-Years
N/A
Cipla Ltd
NSE:CIPLA
Note Receivable
â‚ą3.3B
CAGR 3-Years
1 392%
CAGR 5-Years
45%
CAGR 10-Years
0%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Note Receivable
â‚ą10.9B
CAGR 3-Years
-35%
CAGR 5-Years
-18%
CAGR 10-Years
-2%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Note Receivable
â‚ą2.3B
CAGR 3-Years
87%
CAGR 5-Years
18%
CAGR 10-Years
7%
M
Mankind Pharma Ltd
NSE:MANKIND
Note Receivable
â‚ą1.5B
CAGR 3-Years
0%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Solara Active Pharma Sciences Ltd
Glance View

Market Cap
38.4B INR
Industry
Pharmaceuticals

Solara Active Pharma Sciences Ltd. engages in the manufacture and development of active pharmaceutical ingredient. The company is headquartered in Chennai, Tamil Nadu. The company went IPO on 2018-06-27. The firm is involved in contract manufacturing and development services for global companies. Its commercial products include Aprepitant (Antiemetic), Brivaracetam (Antiepileptic), Bumetanide (Inj) (Loop Diuretic), Buspirone Hcl (Anxiolytic), Cevimeline Hydrochloride (Muscarinic Agonist), Cinacalcet Hydrochloride (Calcimimetic Agent), Citicoline Sodium (Anticonvulsant), Colchicine (Antigout Agent), Disulfiram (Chronic Alcoholism), Edaravone (Recovery Of Stroke), Etomidate (Anesthetics), Felbamate (Anticonvulsant), Flecainide Acetate (Anti-Arrhythmic Agent), Rifaximin (Antibiotic), S-Ibuprofen (Anti-Inflammatory), Oseltamivir Phosphate(Antiviral) and Levetiracetam (Anticonvulsant). The company provides services, such as synthetic development, analytical development, process engineering, and regulatory services.

SOLARA Intrinsic Value
539.44 INR
Overvaluation 33%
Intrinsic Value
Price

See Also

What is Solara Active Pharma Sciences Ltd's Note Receivable?
Note Receivable
39.4m INR

Based on the financial report for Sep 30, 2024, Solara Active Pharma Sciences Ltd's Note Receivable amounts to 39.4m INR.

What is Solara Active Pharma Sciences Ltd's Note Receivable growth rate?
Note Receivable CAGR 5Y
5%

Over the last year, the Note Receivable growth was -22%. The average annual Note Receivable growth rates for Solara Active Pharma Sciences Ltd have been 22% over the past three years , 5% over the past five years .

Back to Top